手性药物(一)——药品和精细化学品工业中的挑战与机会  

Chiral Drugs

作　　者：王普善[1] 王宇梅 

机构地区：[1]国家药品监督管理局信息中心 [2]中国医药(集团)公司

出　　处：《精细与专用化学品》2002年第1期3-6,共4页Fine and Specialty Chemicals

摘　　要：手性药物的研究与开发已成为当今世界新药发展的战略方向和热点领域。1999年,全球手性药物市场销售额第一次超过1000亿美元,达到1150亿美元,比。1998年增长16％,占世界药品市场总销售额3600亿美元的32％。预计2003年将达到1460亿美元,以8％的速度增长。通过外消旋转化、上市药物组合物和开发新型手性单一异构体药物,手性药物正在成为制药公司谋求利益和提升地位的工具。手性中间体、对映选择技术和手性分离技术为精细化学品工业提供了机会。The R&D of Chiral drugs are the strategical direction and hot field of the world's new drugs. In 1999,the sale of chiral drugs was first over 100 billion US dollars and reached to 115 billion US dollars, increasing by 16% in comparison with 1998 and occupying 32% of the total sale of 360 billion US dollars in the world's drugs market. The estimated growth rate will be 8% , reaching 146 billion US dollars in 2003. Through racemic switching, marketing drug combinations and development of new monoisomer, chiral drugs have become important means of making profits and strengthening competitive position for pharmaceutical enterprises. Chiral intermediates, enantiose-lective technology and chiral separation technology have provided opportunity to the fine chemicals industry.

关 键 词：手性药物 药品 精细化学品工业 挑战 外消旋转化 药物组合物 手性中间体 手性技术 

分 类 号：F416.7[经济管理—产业经济]